Imperial Brands' sales boosted by European e-cigarette demand

May.17.2022
Imperial Brands' sales boosted by European e-cigarette demand
Imperial Brands reaches two-year high as strong sales of e-cigarettes and tobacco replacements meet yearly targets.

On May 17th, according to a report by Reuters, Imperial Brands stated on Tuesday that it is expected to achieve its annual goal due to strong sales of electronic cigarettes and heated tobacco products in Europe. This has pushed its stock price to its highest point in over two years.

 

In early trading, shares of Winston cigarettes and Backwoods cigar maker rose nearly 7%, making it the second-best performing company in the STOXX Europe 600 Euro Price Index (.STOXX).

 

Susannah Streeter, senior investment and market analyst at UK investment services company Hargreaves Lansdown, stated: "Investors seem to be breathing a sigh of relief as the company looks set to meet its annual guidance figures, due to its shift towards a five-year strategy focusing on tobacco alternatives.

 

After years of slow growth and market share loss, CEO Stefan Bomhard of Empire Company has developed a turnaround plan for 2021 focusing on its top five markets and expanding the next generation products (NGP) believed to pose lesser health hazards. These five markets - the United States, United Kingdom, Germany, Spain, and Australia - collectively account for over 70% of Empire Company's revenue.

 

Last week, Philip Morris International, a competitor of the Imperial Group, acquired Swedish Match, a smaller competitor, for $16 billion. This highlights the urgency of cigarette manufacturers in developing new and potential low-risk alternative products.

 

Driven by demand in Europe, sales of the next generation brands of the Empire, including Pulze heated tobacco and blu e-cigarettes, grew by 8.7%, reaching £101 million ($126 million). In November, the company reported that losses from the business had reduced by over 50%.

 

The Empire Company also stated that its recent withdrawal from Russia did not include terms that would allow it to buy back its business in the future, as Western companies were eager to leave the country after the invasion of Ukraine.

 

Imperial Company stated in April that investors in Russia were purchasing its business there, which contributes approximately 2% to the company's annual net sales, if merged with Ukraine.

 

During Tuesday's financial report conference call, executives stated that the deal had been finalized with "absolutely no repurchase terms included.

 

On Monday, French car manufacturer Renault announced that it will be selling the majority of its shares in automaker Avtovaz to a Russian scientific research institute for reportedly only 1 ruble, with a buyback option for Renault within 6 years. This move leaves open the possibility of Renault's return to the Russian market.

 

On Tuesday, the Empire Company reported that its adjusted net revenue for the six months ending on March 31 was approximately £3.5 billion, a 0.3% increase in fixed currency. Adjusted earnings per share also rose from 107 pence to 113 pence compared to last year.

 

Source: Reuters

 

Imperial Brands has announced that its sales for the first half of the financial year remained flat, according to a report from Reuters. The tobacco company reported revenue of £3.45 billion ($4.87 billion), which was in line with analysts' expectations. Despite the steady sales figures, the company expressed confidence in its long-term growth prospects and its ability to deliver on its strategic goals. The report also noted that Imperial Brands' rival, British American Tobacco, had reported a 3% decline in its first-quarter revenue due to pandemic-related disruptions.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | JTI Introduces Fully Dissolvable PERLZ Nicotine Pearls in UK, Expands Range From 30-Pearl Dispensers to 10-Pearl Sachets
Product | JTI Introduces Fully Dissolvable PERLZ Nicotine Pearls in UK, Expands Range From 30-Pearl Dispensers to 10-Pearl Sachets
Japan Tobacco International (JTI) has introduced PERLZ nicotine pearls in the UK, expanding its oral nicotine portfolio beyond conventional nicotine pouches. The fully dissolvable, multi-layer pearls are placed under the tongue and come in Mint and Berry flavors at concentrations of 1mg/g and 2mg/g, equivalent to approximately 0.3mg and 0.5mg of nicotine per pearl. UK retailer Haypp published four 30-pearl dispenser listings on July 31, 2026, followed by three 10-pearl sachet products on August 17. The dispensers retail for £6.50, while the sachets cost £2.50.
product
Oct.12
Athletes Back Skoka's $21.5 Million Nicotine Pouch Venture: Can Its Consumer Health Founder Make an FDA-Focused Strategy Pay Off?
Athletes Back Skoka's $21.5 Million Nicotine Pouch Venture: Can Its Consumer Health Founder Make an FDA-Focused Strategy Pay Off?
U.S. nicotine pouch startup Skoka Inc. has raised $21.5 million and committed $15 million to an FDA regulatory and scientific research program. Founder Dan Aziz previously built dietary supplement brand Premama, which was acquired by Dr. Reddy's Laboratories in 2023. Skoka is combining proprietary formulations, ingredient transparency and equity investment from professional athletes. The company submitted a bundled PMTA covering 55 products on October 1, 2026. Aziz said Skoka declined an opportunity to enter retail in 2025, prioritizing product research and regulatory submissions instead. It now targets a U.S. retail launch in 2027, subject to FDA requirements. Its products have not received marketing authorization.
Business
Nov.04
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07
JTI Invests ₱2.1 Billion to Upgrade Batangas Manufacturing Hub, Adds First Southeast Asia DIET Facility
JTI Invests ₱2.1 Billion to Upgrade Batangas Manufacturing Hub, Adds First Southeast Asia DIET Facility
JTI Asia Manufacturing Corp. has invested ₱2.1 billion, or about $37 million, in its manufacturing site in Malvar, Batangas, Philippines, to expand tobacco-processing capabilities. About ₱1.9 billion is allocated to JTI's first Dry Ice Expanded Tobacco, or DIET, facility in Southeast Asia, while more than ₱177 million has been spent on expanding its Controlled Atmosphere treatment facility. The Batangas plant supplies the Philippine market and exports to 22 overseas markets, making it one of JTI's key manufacturing hubs in Asia.
Sep.24
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Raja Krishnamoorthi on Oct. 6 questioned the FDA over its plan to reassess and potentially replace the 2021 PMTA regulatory framework, asking the agency to identify provisions it may change or eliminate, state whether current scientific evidentiary standards will be maintained, and disclose communications with Altria, Reynolds and other parties challenging the rule. Krishnamoorthi led a congressional investigation into JUUL and youth vaping in 2019 and has since remained active on e-cigarette regulation and enforcement.
Regulations
Oct.08
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03